Skip main navigation

Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases


Please take some time to review this essay: Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases

ASO-based therapeutics, being able to modulate disease pathways are potential candidates for the currently incurable genetic neuromuscular diseases. However, current ASOs do not readily cross an intact blood-brain barrier and limit their application via intrathecal injections for central nervous system diseases. Successful ASO development for other neuromuscular diseases that primarily affect peripheral nerves and skeletal muscles will also require efficient delivery methods.

Please explore the biochemical modification of the oligonucleotide. If you are capable, please provide an alternative delivery system. Feel free to leave comments.

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education